MDSC depletion reduced 3LL tumor burden, increased APC activity and augmented splenic T cell cytolytic function.

<p><b><i>2A</i></b><i>,</i> Changes in tumor volume following anti-Gr1 or anti-Ly6G Ab mediated MDSC depletion. <b><i>2B</i></b><i>,</i> Changes in tumor weights for MDSC depleted and control groups (day 21). <b><i>2C</i></b><i>,</i> Representative FACS plots and bar graphs for frequency of CD11b+Gr1+ MDSC in tumor following anti-Gr1 or anti-Ly6G Ab treatment. <b><i>2D</i></b><i>,</i> Representative FACS plots for frequency of CD11b+Gr1+ MDSC in tumor following anti-keratin Ab treatment. <b><i>2E</i></b><i>,</i> Representative APC activity in tumor to activate the CD8 antigen specific T cells to secrete IL-2 following anti-Gr1, anti-Ly6G, isotype control Ab and diluent treatment. <b><i>2F</i></b><i>,</i> CD107a activation marker expression on T cells in tumor following MDSC depletion. <b><i>2G</i></b><i>,</i> Total purified splenic T cell cytolysis against 3LL parental tumor (E:T 10:1, 5:1) for the MDSC depleted groups and isotype controls. There were no differences in T cell cytolysis of parental 3LL cells between the diluent and the isotype control group (data not shown). There were no changes in T cell cytolysis against the non related B16 tumors between the MDSC depleted groups and controls (data not shown). Data in all panels are representative of 2-3 independent experiments (Data, mean ± SEM, p values: compared to controls *p<0.05, **p<0.005, n = 6 mice/group.